Metoprolol Succinate

Metoprolol Succinate is used to treat angina pectoris, atrial fibrillation, atrial flutter, heart failure, hypertension and myocardial infarction, per the National Library of Medicine's MED-RT classification. The brand product was first FDA-approved on Jan 10, 1992, and the first generic was approved Jul 31, 2006. FDA's Orange Book lists 64 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $464 million on Metoprolol Succinate across 32.3 million claims for 7.8 million beneficiaries.

Metoprolol Succinate is available as 164 NDCs from 23 manufacturers (157 generic, 7 brand), with NADAC prices from $0.05 to $3.32 per EA — the most expensive product costs about 67× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.